Dr Shannon Beattie, the company’s chief executive, said the funding round is a “significant” milestone for GenoME, which raised £300,000 in a pre-seed round in 2021.
“Milestones like these will be pivotal in opening conversations with public health bodies and allowing the team to progress our tests further to market. Our ultimate long-term ambition is to eventually enter public screening programmes, however our first market is disease monitoring and diagnosis.” “There is very strong evidence that our technology could be used to diagnose other cancers and illnesses,” he said. “This funding round will enable us to research and test this assumption further, improving the chances for more cancer patients.”
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
ソース: businessposthq - 🏆 8. / 71 続きを読む »
ソース: businessposthq - 🏆 8. / 71 続きを読む »